1. Increased corneal sub-basal nerve density in patients with Sjögren syndrome treated with topical cyclosporine A
- Author
-
Christophe Baudouin, Vincent Borderie, B. Dupas, Laurent Laroche, Ora Levy, Nacim Bouheraoua, Taous Hamiche, and Antoine Labbé
- Subjects
0301 basic medicine ,medicine.medical_specialty ,business.industry ,Sjögren syndrome ,medicine.disease ,Ophthalmic nerve ,Surgery ,03 medical and health sciences ,Ophthalmology ,Basal (phylogenetics) ,030104 developmental biology ,0302 clinical medicine ,medicine.anatomical_structure ,Refractory ,Cornea ,030221 ophthalmology & optometry ,medicine ,Ocular Surface Disease Index ,In patient ,business ,Prospective cohort study - Abstract
Background To evaluate quantitative and qualitative changes in subbasal corneal nerves (SBN) via in vivo confocal microscopy (IVCM) in patients with Sjogren syndrome dry eye (SSDE) treated with topical cyclosporine A (CsA). Design Prospective, observational, non-randomized study. Participants Thirty eyes of 30 patients with SSDE refractory to conventional treatment treated with CsA 0.05% twice daily for six months. Fifteen eyes of 15 healthy, age and gender matched, volunteers constituted the control group at baseline. Methods A clinical evaluation of dry eye (DE), corneal sensation using Cochet-Bonnet esthesiometry and IVCM analysis of the central cornea were performed prospectively at baseline for all patients, and after six months of treatment with CsA. Main outcome measures Density, number, reflectivity and tortuosity of SBN, dendritic cell (DC) density, esthesiometry, and DE signs and symptoms. Results Topical CsA 0.05% improved clinical signs and symptoms, and increased corneal sensitivity. Following treatment, SBN density was significantly increased (P
- Published
- 2017
- Full Text
- View/download PDF